Abstract
Anti-TNF - a agents are used as a reserve treatment for cases of severe psoriasis and psoriatic arthritis that do not respond to conventional therapies. The current use of anti-TNF -a for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) is limited by the clinical observations of the induction of a SLE syndrome. Despite the great number of SLE-like syndromes reported as a side effect of anti-TNF - a blockers, only very few cases of CLE are believed to be a consequence of these drugs. Moreover, on the basis of clinical and laboratory data, anti-TNF -a blockers could be considered as an option for CLE refractory to conventional
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
